title: Detecting of p16 Autoantibody as a Potential Early Diagnostic Serum Biomarker in Patients with Cervical Cancer.
abstract: BACKGROUND
  Over-expression of tumor-associated antigens (TAAs) may trigger secretion of their auto-antibodies. The present work was designed to test whether circulating antibody to P16 protein-derived antigens was altered in cervical cancer.
  
  
  METHODS
  141 cases of cervical cancer patients, 133 cases of cervical benign tumor patients, and 153 healthy volunteers matched in age were recruited. The level of circulating P16 auto-antibody was tested using an ELISA developed in-house with linear peptide antigens derived from the P16 protein.
  
  
  RESULTS
  The P16 auto-antibody in the malignant tumor group had a significantly higher level than the healthy control group and the benign tumor group (t = 4.016, p < 0.001; t = 3.879, p < 0.001). Patients with stage I cervical cancer have the highest level of P16 autoantibody and the sensitivity against > 90% specificity was 20.3%.
  
  
  CONCLUSIONS
  The circulating auto-antibody to P16 may be one of a series of potential biomarkers with early prognostic values for cervical cancer.
authors.forename: Mingmei
authors.initials: M
authors.lastname: Huangfu
authors.forename: Linlin
authors.initials: L
authors.lastname: Liu
authors.forename: Shuang
authors.initials: S
authors.lastname: Xu
authors.forename: Siyao
authors.initials: S
authors.lastname: Li
authors.forename: Kuo
authors.initials: K
authors.lastname: Jiang
authors.forename: Baosheng
authors.initials: B
authors.lastname: Sun
authors.forename: Kuang-Hui
authors.initials: KH
authors.lastname: Lee
authors.forename: Shilong
authors.initials: S
authors.lastname: Sun
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D019941:Cyclin-Dependent Kinase Inhibitor p16; D055088:Early Detection of Cancer / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D015854:Up-Regulation; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000276:immunology* / Q000473:pathology
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins